Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma

Clinical Genitourinary Cancer

Volumn 9, Issue 2, 2011, Pages 81-88

  Manoukian, George E ^a   Tannir, Nizar M ^a   Jonasch, Eric ^a   Qiao, Wei ^a   Haygood, Tamara M ^a   Tu, Shi Ming ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Bisphosphonate; Bone metastasis; Renal cell carcinoma; Statin

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; ATORVASTATIN; DEOXYPYRIDINOLINE; FLUINDOSTATIN; INTERFERON; SORAFENIB; SUNITINIB; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; DEATH; DESQUAMATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEVER; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; PHASE 2 CLINICAL TRIAL; PILOT STUDY; SIDE EFFECT; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BONE REMODELING; CARCINOMA, RENAL CELL; DIPHOSPHONATES; FATTY ACIDS, MONOUNSATURATED; FEMALE; HEPTANOIC ACIDS; HUMANS; IMIDAZOLES; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; PYRROLES; TUMOR MARKERS, BIOLOGICAL;

EID: 80055052513     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2011.07.001     Document Type: Article

References (24)

1. A. Jemal, R. Seigel, and J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. A. Yagoda, B. Abi-Rached, and D. Petrylak Chemotherapy for advanced renal cell carcinoma Semin Oncol 22 1995 42 60
3. J.N. Eble, G. Sauter, and J.L. Epstein International Agency for Research on Cancer World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs 2004 IARC Press Lyon, France
4. H.R. Durr, M. Maier, and M. Pfahler Surgical treatment of osseous metastases in patients with renal cell carcinoma Clin Orthop Relat Res 367 1999 283 290 (Pubitemid 29503706)
5. S.T. Jung, M.A. Ghert, and J.M. Harrelson Treatment of osseous metastases in patients with renal cell carcinoma Clin Orthop Relat Res 409 2003 223 231 (Pubitemid 36417733)
6. N. Tannir, E. Jonasch, and L.C. Pagliaro Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-γ for metastatic renal cell carcinoma Cancer 107 2006 497 505 (Pubitemid 44107209)
7. D.A. Swanson, W.L. Orovan, and D.E. Johnson Osseous metastases secondary to renal cell carcinoma Urology 18 1981 556 561 (Pubitemid 12245439)
8. O.S. Nielsen, A.J. Monro, and I.F. Tannock Bone metastases: pathophysiology and management policy J Clin Oncol 9 1991 509 524
9. J. Zekri, N. Ahmed, and R.E. Coleman The skeletal metastatic complications of renal cell carcinoma Int J Oncol 19 2001 379 382
10. R.J. Motzer, J. Bacik, and M. Mazumdar Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience Clin Cancer Res 10 18 Pt 2 2004 6302S 6303S (Pubitemid 39287482)
11. B. Fuchs, R.T. Trousdale, and M.G. Rock Solitary bony metastasis from renal cell carcinoma: significance of surgical treatment Clin Orthop Relat Res 431 2005 187 192 (Pubitemid 40194235)
12. P.P. Lin, A.N. Mirza, and V.O. Lewis Patient survival after surgery for osseous metastases from renal cell carcinoma J Bone Joint Surg Am 89 2007 1794 1801 (Pubitemid 47229888)
13. A. Lipton, M. Zheng, and J. Seaman Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma Cancer 98 2003 962 969 (Pubitemid 37022096)
14. A. Aparicio, A. Gardner, and Y. Tu In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates Leukemia 12 1998 220 229 (Pubitemid 28108075)
15. A.D. Savage, D.J. Belson, and R.A. Vescio Pamidronate reduces IL-6 production by bone marrow stroma from myeloma patients [abstract] Blood 88 1996 105a
16. C.M. Shipman, P.I. Croucher, and R.G.G. Russell The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway Cancer Res 58 1998 5294 5297 (Pubitemid 28551102)
17. G. Mundy, R. Garrett, and S. Harris Stimulation of bone formation in vitro and in rodents by statins Science 286 1999 1946 1949 (Pubitemid 129515901)
18. P.S. Wang, D.H. Solomon, and H. Mogun HMG-CoA reductase inhibitors and risk of hip fractures in elderly patients JAMA 283 2000 3211 3216 (Pubitemid 30422038)
19. C.R. Meier, R.G. Schlienger, and M.E. Kraenzlin HMG-CoA reductase inhibitors and risk of fractures JAMA 283 2000 3205 3210 (Pubitemid 30422037)
20. A. Horiguchi, M. Sumitomo, and J. Asakuma 3-Hydroxy-3-methylglutaryl- coenzyme A reductase inhibitor, fluvastatin, as a novel agent for prophylaxis for renal cancer cell metastasis Clin Cancer Res 10 2004 8648 8655 (Pubitemid 40053433)
21. M. Rogers Statins: lower lipids and better bones? Nat Med 6 2003 21 23
22. L.M. Demers, L. Costa, and A. Lipton Biochemical markers and skeletal metastases Cancer 88 2000 2919 2926 (Pubitemid 30413174)
23. M. Izumi, Y. Nakanishi, and K. Takayama Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma Cancer 91 2001 1487 1493 (Pubitemid 32319259)
24. R.J. Motzer, J. Bacik, and B.A. Murphy Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 2002 289 296 (Pubitemid 34032623)